Tarsus Pharmaceuticals, Inc.
TARS
Clasificación en acciones
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Precio por acción
$71.12
Capitalización bursátil
$3.33B
Cambio (1 día)
2.33%
Cambio (1 año)
-0.10%
País
US
Comercio Tarsus Pharmaceuticals, Inc. (TARS)
Categoría
Healthcare
Ratio P/B de Tarsus Pharmaceuticals, Inc. (TARS)
Ratio P/B al October 2026 TTM: 9.05
Según los informes financieros más recientes y el precio de las acciones de Tarsus Pharmaceuticals, Inc., el ratio P/B actual (TTM) es 9.05. Al final de 2023, el ratio P/B era 3.02.
Historial del ratio P/B de Tarsus Pharmaceuticals, Inc. desde 2018 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 9.05 | -2.40% |
| 2024 | 9.27 | 207.02% |
| 2023 | 3.02 | 61.44% |
| 2022 | 1.87 | -32.54% |
| 2021 | 2.77 | -45.19% |
| 2020 | 5.06 | -107.57% |
| 2019 | -66.86 | 2.65% |
| 2018 | -65.13 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -30.91% |
US
|
|
| 13.2547 | 46.51% |
US
|
|
| 4.208 | -53.49% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.66% |
NL
|
